

AMENDMENT

In the Claims:

The following listing reflects amendments to the claims and replaces all prior versions and listings of claims in this application.

1-16 (canceled)

17. (Currently amended) An immunogenic composition comprising a first antigen, and a second antigen and an adjuvant, wherein: (a) the first antigen is an oligosaccharide from serogroup C *N. meningitidis* (NmC) conjugated to a carrier; and (b) the second antigen is proteoliposomal vesicles from serogroup B of *N. meningitidis* (NmB).

18. (Previously presented) The composition of claim 17, wherein said first antigen is conjugated to a protein carrier.

19. (Previously presented) The composition of claim 18, wherein said protein carrier is CRM₁₉₇.

20. (Previously presented) The composition of claim 17, wherein said NmC oligosaccharide contains about 12 to about 22 repeating units from *N. meningitidis* serogroup C capsular polysaccharide.

21. (Previously presented) The composition of claim 17, wherein said NmB is strain 44/76 (B15:P1.7, 16:L3,7,9).

22. (Previously presented) The composition of claim 17, wherein said

proteoliposomal vesicles are produced by a deoxycholate extraction process.

23. (Currently amended) The composition of claim 17, wherein said composition further comprises adjuvant is aluminum hydroxide or MF59.

24. (Previously presented) The composition of claim 17, wherein said composition comprises a carrier comprising polylactic acids or polyglycolic acids.

25. (Previously presented) The composition of claim 17, wherein said composition comprises immunologically effective amounts of the first and the second antigen.

26. (Previously presented) An immunogenic composition comprising an immunologically effective amount of a first antigen and an immunologically effective amount of a second antigen, wherein: (a) the first antigen is an oligosaccharide from serogroup C *N. meningitidis* (NmC), conjugated to CRM₁₉₇, and contains from 12 to 22 repeating units from the NmC capsular polysaccharide and (b) the second antigen is proteoliposomal vesicles from strain 44/76 (B15:P1.7, 16:L3,7,9) of serogroup B *N. meningitidis* (NmB), wherein said proteoliposomal vesicles are produced by a deoxycholate extraction process.

27. (Previously presented) The composition of claim 26, wherein said composition further comprises aluminum hydroxide or MF59.

28. (Previously presented) The composition of claim 26, wherein said composition comprises a carrier comprising polylactic acids or polyglycolic acids.

29. (Withdrawn) A method of inducing an immunologic

response to NmB and NmC in a mammalian subject, comprising administering an immunologically effective amount of an immunogenic composition of any of claims 17-28 to said mammalian subject.